Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
Rheum Dis Clin North Am
; 50(2): 269-279, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38670725
ABSTRACT
The introduction of immune checkpoint inhibitors (ICIs) has changed the landscape of the treatment of cancer. Several immune-related adverse events (irAEs) have now been described such as ICI-inflammatory arthritis (IA), sicca syndrome, polymyalgia rheumatica, myositis, and vasculitis as a consequence of immune activation. The onset of the ICI-IA can vary from after the first infusion of ICIs to a delayed presentation a year or more after ICI initiation. Ultimately, baseline patient and tumor characteristics, the types of immunotherapies used, pre-existing autoimmune diseases, and/or other irAEs, as well as patient preferences will all shape the discussions around ICI-IA management.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Artrite
/
Inibidores de Checkpoint Imunológico
Limite:
Humans
Idioma:
En
Revista:
Rheum Dis Clin North Am
/
Rheum. dis. clin. North America
/
Rheumatic disease clinics of North America
Assunto da revista:
REUMATOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos